Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment

Completed

Conditions studied: Cystic Fibrosis

In brief

The goal of this study is to identify chemical compounds in the blood and sputum (i.e., biomarkers) that are associated with objective measurements of health status in patients with cystic fibrosis (CF). This study builds upon observations that blood levels of hepcidin-25, a protein that regulates how the body uses and stores iron, vary during CF pulmonary exacerbation (CFPE).

Key facts

Study ID

NCT02188758

Run by

Dartmouth-Hitchcock Medical Center

People needed

20

Starts

2014-07-01

Expected to finish

2018-01-01

Last updated by the study team

2018-03-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Women who are pregnant or lactating;
• Subject does not meet Inclusion criteria;
• Recent and/or persistent visible blood in sputum (hemoptysis);
• Rescue use of oral antibiotics within the previous 3 weeks, defined as antibiotic use for health deterioration rather than chronic suppression

Where it is running

• Maine Medical Center — South Portland, Maine, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.